Real-time enrollment status for this early-onset alzheimer disease clinical trial
Current Status
Recruiting
Checked: October 18, 2026 at 1:21 AM UTC
| NCT Number | NCT05231785 |
| Recruiting Status | Recruiting |
| Condition | Early-Onset Alzheimer Disease |
| Phase | PHASE1 |
| Target Enrollment | 60 participants |
| Active Locations | 2 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | September 14, 2026 (Sep 14, 2026) |
As of October 18, 2026: Clinical trial NCT05231785 is currently recruiting participants. This phase1 study for early-onset alzheimer disease is actively seeking new participants at 2 locations across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05231785 is actively recruiting participants as of October 18, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 2 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05231785 was last updated Sep 14, 2026 (September 14, 2026). HelloStudys verifies this status automatically.